Everand Logo

Welcome to Everand!

  • STAT

    CRISPR paper that sent stocks tumbling is retracted

    A scientific paper that purported to lay bare serious flaws in the gene-editing tool known as CRISPR has been retracted by its publisher.
    by Meghana Keshavan Mar 30, 2018 1 minute

    A scientific paper that purported to lay bare serious flaws in the gene-editing tool known as CRISPR and briefly tanked shares of genome-editing companies has been retracted by its publisher.

    The , published last year

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Plans For Generic Wegovy, Cough Syrup Warnings, And More
    Biocon is developing a generic version of Novo Nordisk's Wegovy and is prepared to conduct a clinical trial next year if needed.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
    Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
    MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.

    Related